View in EDS HTML Full Text PDF Full Text

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Saved in:
Bibliographic Details
Title: Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.
Authors: Burmester, Gerd R.1 (AUTHOR), Coates, Laura C.2 (AUTHOR), Cohen, Stanley B.3 (AUTHOR), Tanaka, Yoshiya4 (AUTHOR), Vranic, Ivana5 (AUTHOR), Nagy, Edward5 (AUTHOR), Lazariciu, Irina6 (AUTHOR), Chen, All-shine7 (AUTHOR), Kwok, Kenneth6 (AUTHOR), Fallon, Lara8 (AUTHOR), Kinch, Cassandra8 (AUTHOR) cassandra.kinch@pfizer.com
Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p221-222. 2p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21986576
DOI:10.1007/s40744-023-00615-4